Lilly

Covid-19 development round-up: March 4, 2022

The state of the fight: 

Pfizer/BioNTech’s Comirnaty appeared to offer only 12% effectiveness against Omicron in children ages 5-11.
  South Africa’s Biovac partnered with nine development institutions to boost local vaccine manufacturing capacity.
  Eli Lilly’s arthritis drug Olumiant reduced the risk of death by 13% in hospitalized Covid-19 patients.   AUTHORIZED VACCINES

 
Pfizer/BioNTech’s Comirnaty is far less protective against infection in children ages…

Mentions:
Covid-19, vaccines, drugs, Pfizer, BioNTech, Novavax, Sinovac, Valneva, FDA, Bharat Biotech, Inovio, Shionogi, CureVac, GSK, Biovac, Gamaleya Institute, WHO, MPP, Moderna, Bio Farma, ACT-A, EMA, J&J, AstraZeneca, Merck, Regeneron, Roche, Lilly, Gilead, DNDi
Read more
Covid-19 development round-up: February 11, 2022

The state of the fight: 

A Lilly mAb active against Omicron won a U.S. FDA emergency use nod.
  Novavax’s shot proved 80% efficacious in adolescents ages 12-17, according to a Phase 3 readout.
  Vaxxinity’s UB-612 vaccine candidate performed better against Omicron than an mRNA-based comparator jab.

 

AUTHORIZED VACCINES

 
J&J’s single-dose shot was only 53% efficacious against moderate to severe Covid-19 (28 days post-injection) in a final analysis…

Mentions:
Covid-19, vaccines, drugs, J&J, Novavax, FDA, Pfizer, BioNTech, Bharat Biotech, CNBG, Sinopharm, Gamaleya Institute, Sinovac, EMA, AstraZeneca, Walvax, Moderna, Biological E, African Union, COVAX, WHO, ACT-A, Lilly, Gilead, Merck, GSK, Vir, Regeneron, Roche, DNDi, Novartis
Read more
Lilly makes $1 billion manufacturing push

Eli Lilly will invest $1 billion to build a new manufacturing facility for injectable products and devices in North Carolina, creating nearly 600 jobs in the process, the company announced last week.

In other Lilly news, the company on Wednesday announced a commitment of $14.4 million to UNICEF’s work to improve health outcomes in 10 million children and adolescents with noncommunicable diseases in Bangladesh, Malawi, Nepal, the Philippines, and Zimbabwe.

Mentions:
Lilly, manufacturing, UNICEF, NCDs, CSR
Read more
Covid-19 development round-up: January 28, 2022

The state of the fight: 

Moderna and Pfizer/BioNTech launched trials of Omicron-specific vaccine candidates.
  India fully approved SII’s Covishield and Bharat Biotech’s Covaxin shots.
  CEPI tapped BioNet to develop a “variant-proof” pan-coronavirus mRNA-based vaccine.

AUTHORIZED VACCINES  

New data on rates of myocarditis following mRNA-based vaccination trickled in this week, highlighting an increased risk of the heart inflammation side effect in young men…

Mentions:
Covid-19, vaccines, drugs, SII, BBIL, Pfizer, BioNTech, Moderna, J&J, Sinovac, CanSino, AstraZeneca, EMA, FDA, Sanofi, GSK, Novavax, Zydus Cadila, CEPI, COVAX, Gavi, MPP, Merck, Lilly, Regeneron, Roche, Gilead
Read more
Covid-19 development round-up: January 14, 2022

The state of the fight: 

A booster dose of Bharat Biotech’s Covaxin increased neutralizing antibodies up to 265-fold.
  WHO added therapies from Eli Lilly and GSK/Vir to its list of recommended Covid-19 treatments.
  Novartis will pay over $162 million to in-license Molecular Partners’ ensovibep antiviral candidate.

 

AUTHORIZED VACCINES

Two doses of Pfizer/BioNTech’s vaccine reduced the risk of Covid-19 hospitalization by 94% among adolescents ages 12…

Mentions:
Covid-19, vaccines, drugs, Pfizer, BioNTech, AstraZeneca, Moderna, J&J, Janssen, FDA, EMA, BBIL, Novavax, SII, WHO, Sinovac, CanSino, COVAX, UNICEF, Lilly, GSK, Vir, Regeneron, Roche, Merck, Novartis
Read more
Covid-19 development round-up: December 17, 2021

The state of the fight: 

WHO issued an Emergency Use Listing for Serum Institute of India’s version of Novavax’s vaccine.
  The U.S. CDC recommended mRNA-based vaccines over J&J’s.
  Data on the effectiveness of monoclonal antibody therapies against the Omicron variant began pouring in.

AUTHORIZED VACCINES  

A U.S. CDC advisory panel recommended mRNA-based vaccines over the J&J jab, citing blood clot side effects stemming from the single-dose…

Mentions:
Covid-19, vaccines, drugs, Moderna, NIH, J&J, Janssen, Pfizer, BioNTech, CanSino, SII, Novavax, WHO, EMA, COVAX, FDA, Takeda, Butantan Institute, Sinovac, BBIL, Sanofi, GSK, AstraZeneca, Valneva, CNBG, Sinopharm, Gamaleya Institute, Gavi, CEPI, Merck, Regeneron, Roche, Lilly, Vir, Novartis
Read more
Covid-19 development round-up: December 3, 2021

The state of the fight: 

A slew of vaccine manufacturers announced plans to tackle the Omicron variant.
  Aspen Pharmacare and J&J neared a deal that would let the South African manufacturer market its own version of the Janssen shot.
  Gavi’s board approved the alliance’s COVAX strategy for 2022.

AUTHORIZED VACCINES  


New research on the Pfizer/BioNTech shot affirmed its efficacy in younger people and its safety in older people.
 
…

Mentions:
Covid-19, vaccines, drugs, Pfizer, BioNTech, BBIL, FDA, Moderna, Gamaleya Institute, AstraZeneca, CNBG, Sinopharm, J&J, Janssen, Sinovac, Valneva, CEPI, Finlay Institute, Inovio, Novavax, WHO, EMA, Walvax, CureVac, Gavi, COVAX, MPP, Africa CDC, Merck, Lilly, Regeneron, Roche, GSK, Vir, Pfizer
Read more
Covid-19 development round-up: November 19, 2021

The state of the fight: 

U.S. regulators signed off on boosters for all adults.
  India raised a syringe export limit to allow supplies to reach PAHO and UNICEF.
  Pfizer will let Medicines Patent Pool sublicense its oral antiviral to manufacturers in 95 countries.

AUTHORIZED VACCINES  
 

Pfizer/BioNTech’s shot generated stronger antibody responses than three rival vaccines. Comirnaty’s performance bested those of the AstraZeneca/Oxford vaccine, the…

Mentions:
Covid-19, vaccines, drugs, Pfizer, BioNTech, AstraZeneca, Gamaleya Institute, CNBG, Sinopharm, Novavax, SK Bioscience, Moderna, Sinovac, FDA, CDC, CanSino, CureVac, GSK, COVAX, SII, PAHO, UNICEF, Gavi, CEPI, Regeneron, Roche, Lilly, Vir, EMA, Merck, MPP
Read more
Covid-19 development round-up: November 5, 2021

The state of the fight: 

WHO issued an Emergency Use Listing for Bharat Biotech’s Covaxin vaccine.
  Kenya’s Revital Healthcare will more than triple its annual syringe production amid a “looming shortfall” in LMICs.
  Pfizer’s Paxlovid antiviral slashed Covid-19 hospitalizations or death by 89%.

 

AUTHORIZED VACCINES

 
WHO listed Bharat Biotech’s Covaxin vaccine for emergency use on Wednesday, citing 78% efficacy against Covid-19 of any severity…

Mentions:
Covid-19, vaccines, drugs, WHO, BBIL, COVAX, Pfizer, BioNTech, Moderna, J&J, Janssen, Gamaleya Institute, Sinovac, Novavax, SII, CNBG, Sinopharm, AstraZeneca, SK Bioscience, Inovio, CEPI, Africa CDC, Merck, Lilly, MPP
Read more
Covid-19 development round-up: October 15, 2021

The state of the fight: 

A U.S. FDA advisory panel recommended booster shots of the J&J and Moderna vaccines for select groups.
  CureVac will abandon development of its first-generation mRNA-based vaccine candidate.
  Brii Bio has submitted its monoclonal antibody cocktail to the U.S. FDA for Emergency Use Authorization. Approved or authorized vaccines

 
WHO advisory group backs extra dose for immunocompromised: WHO’s Strategic Advisory Group of Experts (…

Mentions:
Covid-19, vaccines, drugs, WHO, Sinovac, CNBG, Sinopharm, Gamaleya Institute, BBIL, Pfizer, BioNTech, Moderna, J&J, Janssen, FDA, Inovio, CureVac, GSK, EMA, Bayer, Bio E, SII, COVAX, AstraZeneca, CEPI, Lilly, Regeneron, Roche, Merck
Read more
Subscribe to Lilly